Table 1.
Positive and negative percent agreement of 12 SARS-CoV-2 antibody assays
| Days from symptom onset | CLIA | EIA | LFIA | sVNT | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbott | Siemens | Roche | Euroimmun | Vircell | BioRad | Boditech | SD biosensor | PCL | Sugentech | Rapigen | GenScript | |||||||||
| IgG (%) | Total (%) | Total (%) | IgA (%) | IgG (%) | IgM+IgA (%) | IgG (%) | Total (%) | IgM (%) | IgG (%) | IgM (%) | IgG (%) | IgM (%) | IgG (%) | IgM (%) | IgG (%) | IgM (%) | IgG (%) | IgG (%) | ||
| PPA | < 8* | 40.0 | 24.0 | 40.0 | 21.1 | 15.8 | 47.4 | 42.1 | 47.4 | 40.0 | 32.0 | 44.0 | 40.0 | 40.0 | 24.0 | 56.0 | 32.0 | 36.0 | 36.0 | 40.0 |
| 8–14† | 71.4 | 63.3 | 75.5 | 82.5 | 55.0 | 72.5 | 77.5 | 90.0 | 73.5 | 75.5 | 83.7 | 69.4 | 83.7 | 71.4 | 91.8 | 73.5 | 87.8 | 75.5 | 85.7 | |
| > 14‡ | 92.3 | 87.7 | 89.2 | 90.0 | 90.0 | 94.0 | 84.0 | 92.0 | 86.2 | 96.9 | 96.9 | 92.3 | 92.3 | 93.8 | 98.5 | 90.8 | 93.8 | 89.2 | 98.5 | |
| NPA | NA§ | 100.0 | 100.0 | 100.0 | 94.9 | 100.0 | 97.4 | 100.0 | 99.5 | 98.5 | 99.0 | 99.0 | 100.0 | 99.0 | 98.5 | 96.4 | 100.0 | 99.0 | 97.9 | NT |
*Includes 25 samples from 22 patients for CLIAs, sVNTs, and LFIAs; 19 samples from 16 patients for EIAs. †Includes 49 samples from 34 patients for CLIAs, sVNTs, and LFIAs; 40 samples from 25 patients for EIAs. ‡Includes 65 samples from 25 patients for CLIAs, sVNTs, and LFIAs; 50 samples from 18 patients for EIAs. §N patients=195.
Abbreviations: PPA, positive percent agreement; NPA, negative percent agreement; CLIA, chemiluminescence immunoassay; EIA, enzyme immunoassay; LFIA, lateral flow immunoassay; sVNT, surrogate virus neutralization test; NA, not applicable; NT, not tested.